Gabasa-Gorgas L, Procas-Ramón B, Ruíz-Martínez S, Hierro-Espinosa C, Polo-Oliveros L, Roldán-Rivas F

Language: Spanish
References: 23
Page: 762-768
PDF size: 843.41 Kb.

ABSTRACT

Background: An adnexal mass can be found in women at any age, and be both benign and malignant. The management varies according to the type of mass, therefore it is important to make a correct differential diagnosis, moreover in young women in which radical surgeries will have a great impact on future fertility.
Clinical case: We report a case of a 19-year-old woman who consulted for abdominal pain. In ultrasound, the presence of a large, heterogeneous hypogastric abdominal mass appears to depend on the ovary. The study was completed by performing a CT scan that confirmed the presence of a mass of 14 cm, with suspicious signs of malignancy. Tumor markers were requested, highlighting the elevation of AFP. With these findings, an exploratory laparotomy was performed with an intraoperative biopsy that reported a germ cell tumor or Yolk Sac tumor. A conservative surgery was performed given the age of the patient and prior to initiating chemotherapy treatment, oocyte cryopreservation was carried out as a fertility preservation technique. Currently the patient follows serial controls and is free of disease.
Conclusions: Finding an adnexal mass in a teenager, requires a thorough study to reach a correct diagnosis, sometimes these masses are malignant and require surgical approach. It is important to perform conservative surgery whenever possible and offer the possibility of preserving fertility.

REFERENCES

1. Nasioisdis D, et al. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol. 2017 Nov; 147 (2): 296-301. doi: 10.1016/j.ygyno.2017.08.013

2. Faure Concer C, et al. Ovarian Yolk Sac Tumors; Does Age Matter? Int J Gynecol Cancer. 2018 Jan; 28 (1): 77-84. doi: 10.1097/IGC.0000000000001149.

3. Inada Y, et al. Rapidly growing juvenile granulosa cell tumor of the ovary arising in adult: a case report and review of the literature. J Ovarian Res. 2018 Dec 14; 11 (1): 100. doi: 10.1186/s13048-018-0474-0.

4. Agarwal R, et al. A retrospective analysis of the pattern of care and survival in patients with malignant ovarian germ cell tumors. South Asian J Cancer. 2019; 8 (1): 35-40. doi: 10.4103/sajc.sajc_6_18.

5. Euscher ED. Germ Cell Tumors of the Female Genital Tract. Surg Pathol Clin. 2019; 12 (2): 621-49. doi: 10.1016/j. path.2019.01.005.

6. Chen LH, et al. Yolk Sac Tumor in an Eight-Year-Old Girl: A Case Report and Literature Review. Front Pediatr. 2019; 7:1 69. doi: 10.3389/fped.2019.00169

7. Kollmannsberger CK, et al. Management of Stage II Germ Cell Tumors: Be Sure, Be Patient, Be Safe. J Clin Oncol. 2019 Jun 10. doi: 10.1200/JCO.19.00502.

8. Luh LCPN, et al. Management comprehensive multidisciplinary of malignant ovarian germ cell tumors and feto - maternal outcome: A case series report and literature review. Maced J Med Sci. 2019 Apr 3; 7 (7): 1174-79. doi: 10.3889/oamjms.2019.251

9. Lavazzo C, et al. Is fertility sparing surgery a treatment option for young patients with yolk sac tumor? Minerva Ginecol. 2018 Dec; 70 (6): 750-53. doi: 10.23736/S0026- 4784.18.04194-1.

10. Nasioudis D, et al. Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecol Oncol. 2017; 147 (3): 493-96. doi: 10.1016/j.ygyno.2017.10.010

11. Park JY, et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2017; 145 (3): 513-18. doi: 10.1016/j.ygyno.2017.03.023

12. Turkmen O, et al. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. J Adolesc Young Adult Oncol. 2017;6 (2): 270-6. doi: 10.1089/jayao.2016.0086.

13. Makris GM, et al. Giving Birth After Fertility Sparing Treatment for a Yolk Sac Tumour: Case Report. J Clin Diagn Res. 2017 Aug; 11 (8): QD12-QD13. doi: 10.7860/ JCDR/2017/25820.10524

14. Dunn TN, et al. Successful yolk-sac tumor treatment with fertility-sparing partial oophorectomy. Gynecol Oncol Rep. 2018 Nov 30; 27: 22-24. doi: 10.1016/j.gore.2018.11.007.

15. Qin B, et al. Are omentectomy and lymphadenectomy necessary in patients with apparently early-stage malignant ovarian germ cell tumors?. Int J Gynecol Cancer. 2019. doi: 10.1136/ijgc-2018-000078.

16. Li J, Wu X. Current strategy for the treatment of ovarian germ cell tumors: Role of extensive Surgery. Curr Treat Options Oncol. 2016; 17 (8): 44. doi: 10.1007/s11864- 016-0416-2.

17. Park JY, et al. Outcomes of surgery alone and surveillance strategy in young women with stage I malignant ovarian germ cell tumors. Int J Gynecol Cancer. 2016; 26 (5): 859- 64. doi: 10.1097/IGC.0000000000000702

18. Satoh T, et al. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer. 2015; 51 (3): 340- 51. doi: 10.1016/j.ejca.2014.12.004

19. Zhang GY, et al. Neoadjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy in the treatment of extensively advanced yolk sac tumors: A single center experience. Int J Gynecol Cancer. 2018 May; 28 (4): 713-20. doi: 10.1097/ IGC.0000000000001209.

20. Newton C, et al. A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Eur J Cancer. 2019; 113: 19-27. doi: 10.1016/j. ejca.2019.03.001.

21. De La Motte RT, et al. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol. 2008; 19 (8): 1435-41. doi: 10.1093/annonc/mdn162

22. Satoh T, et al. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer. 2015; 51 (3): 340- 51. doi: 10.1016/j.ejca.2014.12.004.

23. Chatchotikawong U, et al. 8-year analysis of the prevalence of lymph nodes metastasis, oncologic and pregnancy outcomes in apparent early-stage malignant ovarian germ cell tumors. Asian Pac J Cancer Prev. 2015; 16 (4): 1609-13.